With Glyco (Double) Delete we have developed a disruptive - and IP protected - technology that fundamentally solves the problem of glycosylation heterogeneity in the production of proteins in eukaryotic cells. The Glyco (Double) Delete technology platform has the potential to accelerate the characterization and validation process of both new and existing glyco-pharmaceuticals, and can accelerate the flow of new therapeutics to the market. The aim of this project is to further develop the technology so that a spin-off company can be established that optimally captures the value of the Glyco (Double) Delete and GlyConnect technology